Alector, Inc. (NASDAQ:ALEC - Get Free Report)'s stock price was up 7% during trading on Monday . The stock traded as high as $5.42 and last traded at $5.37. Approximately 513,481 shares were traded during trading, a decline of 16% from the average daily volume of 609,598 shares. The stock had previously closed at $5.02.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reiterated an "overweight" rating on shares of Alector in a research report on Tuesday, September 17th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $17.75.
Get Our Latest Stock Analysis on Alector
Alector Stock Up 5.0 %
The stock has a market cap of $512.88 million, a price-to-earnings ratio of -2.93 and a beta of 0.66. The company's 50-day simple moving average is $5.05 and its 200-day simple moving average is $5.11.
Alector (NASDAQ:ALEC - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.09. Alector had a negative return on equity of 102.63% and a negative net margin of 290.66%. The company had revenue of $15.08 million for the quarter, compared to analyst estimates of $16.04 million. During the same period in the previous year, the firm earned $0.02 earnings per share. As a group, analysts expect that Alector, Inc. will post -1.92 EPS for the current fiscal year.
Insider Activity
In related news, insider Sara Kenkare-Mitra sold 13,926 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total value of $67,958.88. Following the completion of the sale, the insider now directly owns 291,715 shares of the company's stock, valued at approximately $1,423,569.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Sara Kenkare-Mitra sold 13,926 shares of Alector stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $67,958.88. Following the completion of the sale, the insider now owns 291,715 shares of the company's stock, valued at approximately $1,423,569.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Paula Hammond sold 10,500 shares of Alector stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $5.06, for a total value of $53,130.00. Following the sale, the director now owns 60,209 shares of the company's stock, valued at approximately $304,657.54. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 58,222 shares of company stock worth $286,013 over the last 90 days. 9.10% of the stock is owned by company insiders.
Institutional Investors Weigh In On Alector
A number of large investors have recently bought and sold shares of ALEC. Vanguard Group Inc. lifted its position in shares of Alector by 12.0% in the first quarter. Vanguard Group Inc. now owns 4,912,578 shares of the company's stock worth $29,574,000 after buying an additional 526,037 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Alector by 211.6% during the first quarter. Acadian Asset Management LLC now owns 444,647 shares of the company's stock valued at $2,675,000 after purchasing an additional 301,936 shares during the last quarter. Panagora Asset Management Inc. raised its position in shares of Alector by 61.7% in the second quarter. Panagora Asset Management Inc. now owns 355,318 shares of the company's stock valued at $1,613,000 after purchasing an additional 135,614 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of Alector by 16.2% in the first quarter. Jacobs Levy Equity Management Inc. now owns 922,799 shares of the company's stock valued at $5,555,000 after purchasing an additional 128,515 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of Alector in the first quarter worth $760,000. 85.83% of the stock is currently owned by institutional investors.
About Alector
(
Get Free Report)
Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.
Further Reading
Before you consider Alector, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alector wasn't on the list.
While Alector currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
